Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2026)

Harmony Biosciences Holdings' Net Margin history runs 7 years deep, the most recent figure standing at 15.08% for Q1 2026.

• In Q1 2026, Net Margin fell 958.0% year-over-year to 15.08%; the TTM figure through Mar 2026 stood at 17.82% (down 664.0% YoY), while the FY2025 annual figure was 19.96%, down 452.0% from the prior year.
• Net Margin came in at 15.08% for Q1 2026 at Harmony Biosciences Holdings, down from 15.22% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 75.03% in Q3 2022 to a low of 29.18% in Q4 2022.
• A 5-year average of 22.04% and a median of 24.0% in 2023 frame the typical range for Net Margin.
• On a YoY basis, Net Margin climbed as much as 8695 bps in 2022 and fell as far as 5408 bps in 2022.
• Harmony Biosciences Holdings' Net Margin stood at 29.18% in 2022, then soared by 154 bps to 15.8% in 2023, then surged by 148 bps to 39.22% in 2024, then sank by 61 bps to 15.22% in 2025, then declined by 1 bps to 15.08% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 15.08%, 15.22%, and 21.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison